Clinical Scorecard: Adherence to Allopurinol in Newly Diagnosed Gout Patients and Its Association with Fracture Risk: A Nationwide Cohort Analysis

At a Glance

Key Highlights

• Gout incidence and prevalence have increased significantly over the last two decades.
• Medication adherence among gout patients is often poor, impacting treatment outcomes.
• The relationship between gout and fracture risk remains controversial.
• The study utilized a large-scale cohort to assess the impact of allopurinol adherence on fracture risk.
• Fractures were categorized into vertebral, hip, and distal radius types.

Guideline-Based Recommendations

Diagnosis

• Diagnosis of gout is based on ICD-10 code M10 and clinical presentation.

Management

• Urate-lowering therapy (ULT) is indicated for patients with recurrent flares or comorbidities.

Monitoring & Follow-up

• Medication possession ratio (MPR) should be assessed to evaluate adherence to allopurinol.

Risks

• Potential increased fracture risk in gout patients, though evidence is conflicting.

Patient & Prescribing Data

4,107 patients newly diagnosed with gout and prescribed allopurinol.

Adherence to allopurinol therapy is crucial for managing gout and potentially influencing fracture risk.

Clinical Best Practices

• Encourage regular monitoring of medication adherence in gout patients.
• Educate patients on the importance of consistent urate-lowering therapy.
• Consider individual patient factors when assessing fracture risk.

Related Resources & Content

• National Health Insurance Service-National Health Screening Cohort